Myriad Genetics details separation terms for former chief commercial officer

Myriad Genetics disclosed in an 8-K that on October 6, 2026, the company entered into a Separation Agreement and Release of Claims with Brian Donnelly, the company's former Chief Commercial Officer.¹

The filing notes that Donnelly had already departed from the Chief Commercial Officer role effective September 16, 2026, with his employment formally ending at the close of business on September 21, 2026, designated as the Separation Date.¹ The Separation Agreement itself becomes effective on October 14, 2026, as long as Donnelly does not revoke it before that date.¹

Under the agreement's terms, Donnelly will receive a lump sum severance payment of $1,322,294 in exchange for compliance with restrictive covenants such as non-solicitation and non-disparagement provisions, along with a standard release of claims against the company.¹

The agreement also addresses equity compensation. Time-based equity awards that were set to vest within two years of the Separation Date will have their vesting accelerated to the Separation Date, with annual vesting installments converted to monthly installments over that two-year span. Performance-based equity awards with conditions not yet met will remain outstanding, and if those conditions are satisfied within the same two-year period, the awards will vest to the extent scheduled within that window.¹

The severance and related consideration are being provided under the terms of Donnelly's existing Severance and Change of Control Agreement.¹ The full separation agreement is attached to the filing as Exhibit 10.1.¹ The 8-K was signed by Chief Financial Officer Benjamin R. Wheeler and dated October 9, 2026.